Accessibility Menu
 
Quoin Pharmaceuticals logo

Quoin Pharmaceuticals

(NASDAQ) QNRX

Current Price$6.40
Market Cap$9.41M
Since IPO (2021)-100%
5 Year-100%
1 Year-26%
1 Month-25%

Quoin Pharmaceuticals Financials at a Glance

Market Cap

$9.41M

Revenue (TTM)

$0.00

Net Income (TTM)

$15.80B

EPS (TTM)

$-460.50

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$6.40

Volume

6,545

Open

$6.16

Previous Close

$6.40

Daily Range

$6.16 - $6.83

52-Week Range

$5.01 - $41.80

QNRX News

QNRX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quoin Pharmaceuticals

Industry

Biotechnology

Employees

4

CEO

Michael Myers, PhD

Headquarters

Ashburn, VA 20148-7349, US

QNRX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-143%

Return on Capital

-0%

Return on Assets

-78%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.41M

Shares Outstanding

1.50M

Volume

6.54K

Short Interest

0.00%

Avg. Volume

98.83K

Financials (TTM)

Gross Profit

$100.79K

Operating Income

$16.42M

EBITDA

$16.42M

Operating Cash Flow

$13.54B

Capital Expenditure

$4.00

Free Cash Flow

$13.54B

Cash & ST Invst.

$3.82B

Total Debt

$0.00

Quoin Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$25.16K

N/A

Gross Margin

0.00%

N/A

Market Cap

$9.41M

N/A

Market Cap/Employee

$3.14M

N/A

Employees

3

N/A

Net Income

$15.79B

-683211.4%

EBITDA

$4.55M

-91.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$3.82B

+27061.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-77.51%

N/A

Return on Invested Capital

-0.11%

N/A

Free Cash Flow

$13.53B

-604969.2%

Operating Cash Flow

$13.53B

-604969.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VYNEVYNE Therapeutics Inc.
$0.60+1.62%
PLRZPolyrizon Ltd.
$11.68-1.68%
TCRTAlaunos Therapeutics, Inc.
$2.86+1.42%
CYCNCyclerion Therapeutics, Inc.
$1.55+7.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$41.68+0.10%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.55-0.11%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$80.49-0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.15+0.09%

Questions About QNRX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.